VTRS (Viatris) Short Percentage of Float

View and export this data going back to 1973. Start your Free Trial

What is Viatris Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Viatris's Short Percentage of Float

For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viatris's Short Percentage of Float Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Viatris's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Viatris's Short Percentage of Float falls into.

Save Embed

;

Save Embed

;

Viatris Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (NAS:VTRS) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

MYL:Mexico 1VTRS:Italy 0A5V:UK VIA:Germany VIA:Germany VIA:Germany VIA:Germany MYL:Austria

Address

1000 Mylan Boulevard, Canonsburg, PA, USA, 15317

Website

https://www.viatris.com

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Executives

Scott Andrew Smith	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Paul Campbell	officer: See Remarks	BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL
Rajiv Malik	director, officer: President	BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL
Brian Roman	officer: Global General Counsel	1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Anthony Mauro	officer: See Remarks	BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL
Dillon Joellen Lyons	director	BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HARTFORDSHIRE X0 AL 109UL
Xiangyang (sean) Ni	officer: President, Greater China	1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Andrew Cuneo	officer: See Remarks	1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Harry Korman	director	BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL
Leo Frans Groothuis	director	1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Elisha W Finney	director	C/O VARIAN MEDICAL SYSTEMS, INC, 3100 HANSEN WAY M/S E-327, PALO ALTO CA 94304
Van Der Meer Mohr Pauline	director	1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Menassie Taddese	officer: See Remarks	1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Robert J Coury	director, officer: Executive Chairman	BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL
W Don Cornwell	director